Method for inhibiting Zika virus infection

US11878004B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• Florida State University Research Foundation, Inc. · US
• The Trustees of the University of Pennsylvania · US

Inventors

• Hengli Tang · Tallahassee, US
• Emily M. Lee · Tallahassee, US
• Wei Zheng · Rockville, US
• Ruili Huang · Rockville, US
• Miao Xu · Hangzhou City, CN
• Wenwei Huang · Rockville, US
• Khalida Shamim · Gaithersburg, US
• Guoli Ming · Philadelphia, US
• Hongjun Song · Madison, US

Key dates

• Filing date: Jun 28, 2022
• Grant date: Jan 23, 2024
• Expiry date: Jul 21, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.